The COVID-19 pandemic has devastated economic and public health, and healthcare industry has been busy developing the vaccines, antivirals, and supportive treatments which is a time-consuming process in order to develop drugs and get approval.
Unlike other industries, COVID-19 pandemic has further created opportunities for the biotechnology companies to utilise the opportunity and showcase the capabilities of computer aided drug design and development.
Increasing cost of drug development and lack of new chemical entities are the growing concerns for new development of drugs. COVID-19 is providing greater opportunities for drug repurposing activities and companies are increasingly using computer aided drug discovery to study the existing drug effects on COVID-19.
There have been major developments in In-Silico Drug repurposing across the world, where they develop new use to an old existing drug, which is a cost effective strategy to develop drug for COVID-19.
With the outbreak of SARS-CoV-2 virus causing the COVID-19 pandemic, and researchers are turning towards computer simulations and AI technologies to identify potential treatments.
For instance, in June 2020, Delta 4, a biotech company has applied its drug discovery platform to identify and shortlisting potential COVID-19 drug using computer models
Increasing laboratories, researchers and drug development organisations are using of AI(artificial Intelligence), quantum mechanical scoring, and other computer simulation and genomic analysis methodologies.
For instance, In June 2020, Ennaid Therapeutics are developing antiviral drugs for COVID-19 using AI-based drug discovery platforms. ENU200, a repurposed orally deliverable antiviral drug is able to treat up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections. The company yet to avail approvals for use in COVID-19.
Request Sample at : https://www.globalmonitor.us/product/global-computer-simulated-drug-discovery-market
Segmentation by Product
Drug designing and development are the key stages in the In-Silico drug discovery process that allow for the clinical trials make it to the market.
Over the last three decades software based drug development has played an important role in the development of bioactive compounds.
Structure-based drug design, molecular modelling, structure-based virtual screening, ligand interaction, and molecular dynamics are the key software methods of developing a drug.
Computational methods such as docking confer interaction of small molecules with structural macro-molecules are used in identification and lead optimisation.
Currently, the software methods are exhibiting a domineering role in different phases of drug discovery, especially in biomedicine sciences.
New technologies such as virtual reality and AI are further adding enhanced opportunities for the drug discovery.
For instance, in May 2020, Nanome, Inc., a virtual reality (VR) startup and In-Silico Medicine, an artificial intelligence company have published a paper on developing 10 potential small molecule inhibitors targeting the SARS-CoV-2 main protease using AI.
In-Silico has previously been successful in designing small molecule drugs for a wide range of human diseases, such as cancer, fibrosis, and immunological diseases.
Segmentation by Geography
United States and China is being one of the prominent region for In-Silico drug discovery market.
China is increasingly contributing to the industry in recent years. The growth and increasing adoption in the country is mainly due to increasing development of various products by international giants and local players.
The country is expected to showcase strong growth over the forecast period at aCAGR of around 11%.
The anticipated growth in the country is mainly due to various government initiatives to incorporate drug discovery methodologies as a standard approach in their healthcare systems.
InOctober 2019, In-Silico Medicine in collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH) has signed a dual-program discovery, which worth up to USD 200 million.
In-Silico has recently raised USD 37 million in a series B round to further enhance AI-based pharma partnerships from China-based Qiming Venture Partners besides Eight Roads, Sinovation Ventures, Baidu Ventures, Deep Knowledge Ventures, F-Prime Capital, Lilly AsiaVentures, and others.
Emphasis on reduction in medical errors and readmission rates, growth in the biomarker identification market and advancements in In-Silico drug discovery techniques, and technical advancements in the computational biology are some of the key factors contributing to the growth of the computer modeled drug discovery market. Further, Software based drug development helps in eliminating the rate of errors and improve the accuracy and accessibility and because of this drug discovery using computer models is offering a great growth opportunities to reduction in medical errors in developing new drugs
Some of the key challenges faced in the computer simulated drug discovery market are lack of high complexity testing centres, expensive procedure and their application in treatment, and high capital requirement for global expansion. The need for high investment in the infrastructure is the key drawback for the companies to invest in computer aided drug development. The capital investment required varies based on the size and capabilities of the laboratory.
Table of Contents
1. Research Methodology and Scope
2. Executive Summary
3. Market Dynamics
3.3 Porters Five Forces Analysis
4. Industry Regulations
5. Competitive Landscape
6. Computer Simulated Drug Discovery Market by Workflow
6.1 Target Identification
6.1.2 Reverse Docking
6.1.3 Protein StructurePrediction
6.2 Target Validation
6.3 Lead Discovery
6.3.1 Library Design
6.4 Pre-Clinical Tests
6.5 Clinical Trials
7. Computer Simulated Drug Discovery Market by Product
7.3 Consultancy as a Service
8. Computer Simulated Drug Discovery Market by Software
8.1 Molecular Modelling and de NovoDrug Design Software
8.2 Pharmacophore Modelling Software
9. Computer Simulated Drug Discovery Market by End-User
9.1 Contract Research Organisations
9.2 Pharmaceutical Industry
9.3 Academic and Research Institutes
10. Computer Simulated Drug Discovery Market by Region
10.1 North America
10.1.1 United States
10.2.1 United Kingdom
10.2.6 Rest of Europe
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 South America
10.4.2 Rest of South America
10.5 Middle East and Africa
11. Company Profiles
11.1 Albany Molecular Research
11.2 Charles River
11.4 Simulation Plus
11.6 Dassault System
11.7 WuXi AppTec
11.8 Certara USA, Inc
11.9 Collaborative Drug Discovery Inc
11.10 PerkinElmer, Inc
Phone: +1 206 809 0882